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ABSTRAK
Keganasan pada paru terdiri dari banyak tipe yang secara klinis dibedakan menjadi SCLC dan NSCLC. Small cell lung cancer 
(SCLC) merupakan 20% dari keganasan paru yang secara morfologi merupakan neoplasma neuroendokrin. Kasus combined SCLC 
ini merupakan salah satu tipe SCLSC yang dilaporkan karena kejarangannya. Insiden yang dilaporkan adalah sekitar 1-14,6% dari 
semua tipe SCLC. Secara fenotip gambaran morfologinya merupakan campuran dari SCLC dan NSCLC, sehingga terkadang diagnosis 
dengan menggunakan pengecatan rutin akan sangat sulit dilakukan. Selain itu c-SCLC adalah tipe SCLC yang sangat agresif. Pada 
kasus ini dilaporkan seorang laki-laki yang dirujuk karena adanya masa soliter paru disertai metastasis di otak dan limfonodi. Diagnosis 
histopatologi menunjukkan gambarna campuran dari adenokarsinoma, karsinoma sel skuamosa dan karsinoma large cells. Dilakukan 
panel imunohistokimia meliputi CK-7, CK-20, TTF-1, P63 dan Chromoganin, sehingga dapat dipastikan diagnosisnya sebagai c-SCLC. 
Kata kunci: combined SCLC, nodul soliter.
ABSTRACT
Lung cancer is a large heterogeneous family of malignancies, with tumors containing more than one subtype are very common. Over 50 different histologi-
cal variants are recognized within the WHO typing system. Small Cell Lung Cancer comprises approximately 20% of all lung cancers and exhibits a 
neuroendocrine phenotype while Non Small Cell Lung Carsinoma (NSCLC) lacks these features and makes up the remaining 80% of cases. This case 
was reported in view of the rarity of this combination of morphologic patterns. The incidence of c- SCLC (Combined- Small Cell Lung Carsinoma) has 
been reported ranging from less than 1% to 14.6% of all SCLC. Mixed lung cancer in untreated patients suggests a common endodermal origin for c-SCLC 
which contains small-cell and non-small-cell pulmonary tumors. Quoix et al found that presentation as a solitary pulmonary nodule (SPN) is particularly 
indicative of a c-SCLC. Combined- Small Cell Lung Carsinoma contains a squamous cell and/or adenocarcinoma component. It’s becoming more 
important for pathologists to correctly subclassify NSCLC’s as distinct tumor entities, or as components of c-SCLC cause it’s more agrresive. A 46-year-old 
smoker man was referred because of rapid growth of a solitary nodule mass revealed by chest radiography with brain and limfonodes metastases. There 
was mixed histological feature including adenocarsinoma, squamous cell carsinoma and large cell carsinoma. The patient is dead after a few weeks later. 
It was revealed a panel immunohistochemistry stain (CK-7, CK-20, TTF-1, P63 and Chromoganin). It was concluded as c- SCLC. 
Keywords: Mixed lung cancer, combined Small Cell Lung Carsinoma (c-SCLC), solitary nodul
INTRODUCTION 
Lung cancer is a large heterogeneous family 
of  malignancies, with tumors containing more than 
one subtype being very common. Over 50 different 
histological variants are recognized within the World 
Health Organization (WHO) typing system. Tobacco 
smoke is a major etiological factor, especially in Small 
cell lung carsinoma (SCLC). Small cell lung carsinoma 
comprises approximately 20% of  all lung cancers and 
exhibits a neuroendocrine phenotype while Non Small 
Cell Lung Carsinoma (NSCLC) lacks these features 
and makes up the remaining 80% of  cases (Travis 
characterized by mixed histology feature. Mixed 
lung cancer in untreated patients suggests a common 
endodermal origin for Combined- Small Cell Lung 
Carsinoma (c-SCLC) which contains small-cell and non-
small-cell pulmonary tumors (Roggli, et al., 1985).
However, since there are different forms of  
malignant tumors generally exhibit diverse genetic, 
biological, and clinical properties, including response 
to treatment, accurate classification of  lung cancer 
cases are critical to assuring that patients with lung 
cancer receive optimum management. With the use 
of  “molecularly targeted” agents, it is becoming more 
important for pathologists to correctly subclassify 
NSCLC’s as distinct tumor entities, or as components 
Copyright @ 2016 Authors. This is an open access article distributed under the terms of  the Creative Commons Attribution-NonCommercial-
ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-nc-sa/4.0/), which permits unrestricted non-commercial 
use, distribution, and reproduction in any medium, provided the original author and source are properly cited.
CASE REPORT: 
et al., 2004). Small cell lung cancer exhibits a more 
aggressive phenotype. Mixed lung cancer is neoplasm 
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of  c-SCLC’s. This case was reported in view of  the 
rarity of  this mixed of  morphologic patterns, and it 
was revealed a panel immunohistochemistry stain (CK-
7, CK-20, TTF-1, P63 and Chromoganin) to conclude 
whether it was c- SCLC or other type of  lung cancer. 
There were some difficulties to diagnose this case 
based on Hematoxilyn eosin stain only. This case was 
among the most challenged case for pathologist. Mixed 
histological features could drive to wrong interpretation 
and finally wrong management. The incidence of  c- 
SCLC has been reported ranging from less than 1% 
to 14.6% of  all SCLC.
CASE REPORT
A 46-year-old smoker man presented at a local 
clinic complaining cough almost for 1 year, but as chest 
radiography revealed there were no abnormalities, he 
was released and followed up by radiology screening. 
One month later he coughed out hemosputum and 
experiencing dispnea, he returned to the same clinic 
and the patient was therefore referred to our hospital. 
He was referred because of  rapid growth of  a solitary 
nodule mass indicated by chest radiography with brain 
and limfonodes metastases. Chest radiography revealed 
a mass lesion in the right mid-lung field and bilateral 
pleural effusion. Chest computed tomography (CT) 
was performed on admission revealed a mass in S 4-
5 of  the right lung, infiltrate to the right Pulmonary 
artery, and also hilar limfonodes (fig. 1).
Cranial magnetic resonance imaging on Figure 2 
revealed a mass, while abdominal CT (Figure 1) revealed 
multiple noduls in the liver, and limfadenopathy of  
right paratracheal region. Bone scintigraphy revealed 
metastatic on processus trasversus veterbrae thorac 
3,5,7,9,10,11 and lumbal 1. The limfonode biopsy two 
days later by the surgeon, revealed tumor cell with 
increased chromatin and round nuclei with a high 
nuclear/cytoplasmic ratio, and abundant cytoplasm 
with intercellular bridges, clear cytoplasm, prominent 
nucleoli, and keratin. Trans thoracal needle biopsy and 
pleural effusion revealed features of  adenocarsinoma, 
squamous cell carcinoma and large cell carsinoma, 
namely proliferation of  medium- large carcinoma cells 
with increased chromatin, round nuclei with a high N/
C ratio. There were abundant cytoplasm respectively, 
and small areas of  artefactually crushed cells and nuclei, 
rosset and ink blot appearance. It was conclude as 
mixed histological feature of  small cell carcinoma, 
squamous cell carsinoma, adenocarsinoma and large 
cell carsinoma. Microscoping finding with Hematoxilyn 
eosin staining showed here (Figure 3.). 
The tumor was diagnosed as c- SCLC based 
Figure 1.  CT scan show a mass in S 4-5 of the right lung 
and multiple nodul in the liver. 
Figure 2.  The arrow showed a single nodule in the 
brain.
Figure 3.  Lymphonodes biopsy. A. HE. Staining 20x. 
B. HE staining 40x. C. CK7 staining. D. 
Chromoganin staining.
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on the findings of  the rapid enlargement of  the tumor 
and mixed histological feature of  limfonode biopsy, 
transthoracal biopsy and pleural effusion cytology. 
Therefore, patient was administered paliatif  treatment 
designed for cT4N1M1 c- SCLC. However, the clinical 
presentation became worsen and the patient was death 
after a few weeks later. 
Immunohistochemical examination performed 
on each component showed negative staining for TTF-
1, and CK-20, positive staining for CK-7 and AE1/3 on 
the membrane of  cytoplasm and the cytoplasm, positive 
for P63 in the cytoplasm and the nuclear, and partial 
positive for Chromoganin in the cytoplasm (Figure 
3). Based on these results, the patient was diagnosed 
as combined small cell carcinoma containing three 
malignant components: large cell carsinoma, squamous 
cell carcinoma and adenocarsinoma cell carcinoma.
DISCUSSION
There were some difficulties to diagnose this 
case based on Hematoxilyn eosin stain only. This case 
is among the most challenging case of  pathologist. It 
is rare and more aggresive. Mixed histological features 
could lead to wrong interpretation and finaly wrong 
management. Under WHO-2004, lung carcinomas 
are divided into 8 major taxonomy namely: squamous 
cell carcinoma, small cell carcinoma, adenocarcinoma, 
large cell carcinoma, adenosquamous carcinoma, 
sarcomatoid carcinoma, carcinoid tumor, salivary 
gland-like carcinoma.
SCLC is generally considered to be the most 
aggressive form of  lung cancer, with the worst long 
term prognosis and survival rates. Small cell lung cancer 
comprises approximately 20% of  all lung cancers and 
exhibits a neuroendocrine phenotype while NSCLC 
lacks these features and makes up the remaining 
80% of  cases. Small cell lung cancer exhibits a more 
aggressive phenotype (Roggli VL et al., 1985, Travis 
et al., 2004) .
Mixed lung cancer in a smoker, old untreated 
patients suggests a common endodermal origin for c-
SCLC which contains small-cell and non-small-cell 
pulmonary tumors. Quoix et al (1990) found that 
presentation as a solitary pulmonary nodule (SPN) is 
particularly indicative of  a c-SCLC. Combined- Small 
Cell Lung Carsinoma contains a squamous cell and/or 
adenocarcinoma component. The incidence of  c- SCLC 
has been reported to range from less than 1% to 14.6% 
of  all SCLC. In a study of  408 consecutive patients 
with SCLC, Quoix et al (1990) found that presentation 
as a solitary pulmonary nodule (SPN) is particularly 
indicative of  a c-SCLC about 2/3 of  their SPN’s were 
pathologically confirmed to be c-SCLC’s containing a 
large cell carcinoma component (Masashi G et al., 2004; 
Choe B.P et al., 2006; Quoix et al., 1990). 
In the view of  the evident hilar adenopathy, rapid 
enlargement of  the tumor, and long distance metastases, 
this man suggested to develop a small cell carsinoma. 
Based on clinical finding, radiological examination 
and histopathological approach, it was concluded as c- 
SCLC. In most cases, lung cancers probably result from 
the malignant transformation of  a single multipotent 
cell. Approximately 98% of  lung cancers are carcinoma, 
a term which implies that the tumor derives from 
transformed epithelial cells, or consists of  cells that 
have acquired epithelial characteristics as a result of  
cell differentiation (Patrick L et al., 2009). In most 
cases of  c-SCLC, genomic and immunohistochemical 
studies suggest that the morphological divergence of  
the separate components in a c-SCLC occurs when 
a SCLC-like cell is transformed into a cell with the 
potential to develop NSCLC variant characteristics, and 
not vice versa. Daughter cells of  this transdifferentiated 
SCLC-like cell then repeatedly divide and, under 
both intrinsic genomic and extrinsic environmental 
influences, acquire additional mutations, a process 
known as tumor progression. The end result is that 
the tumor acquires specific cytologic and architectural 
features suggesting a mixture of  SCLC and NSCLC 
(Tatematsu A et al., 2008). Other molecular studies, 
however, suggest that - in at least a minority of  cases, 
independent development of  the components in c-
SCLC occurs via mutation and transformation in two 
different cells in close spatial proximity to each other, 
due to field cancerization. In these cases, repeated 
division and mutational progression in both cancer 
stem cells generate a biclonal collision tumor (Zhang 
H et al., 2005; Zamecnik J et al., 2002)
Regardless of  which of  these mechanisms give 
rise to the tumor, recent studies suggest that, in the later 
stages of  c-SCLC oncogenesis, continued mutational 
progression within each tumor component results in 
the cells of  the combined tumor developing molecular 
profiles that more closely resemble each other than 
they do cells of  the “pure” forms of  the individual 
morphological variants (Aoyagi Y et al., 2001). This 
molecular oncogenetic convergence likely has important 
implications for treatment of  these lesions, given the 
differences between standard therapeutic regimens 
for SCLC and NSCLC. Combined- Small Cell Lung 
Carsinoma also occurs quite commonly after treatment 
of  “pure” SCLC with chemotherapy and/or radiation, 
probably as a result of  a combination of  tumor genome-
specific “progressional” mutations, stochastic genomic 
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phenomena, and additional mutations induced by the 
cytotoxic therapy (Radice PA, et al., 1982). There was no 
evidence of  theraupetic transformation induced on this 
patient because he never get radiation or chemotherapy 
treatment before he was referred. The most common 
forms of  NSCLC identified as components within c-
SCLC are large cell carcinoma, adenocarcinoma, and 
squamous cell carcinoma. Rarer variants of  NSCLC 
are seen less commonly, such as combinations with 
carcinoids, spindle cell carcinoma, and giant cell 
carcinoma (Masashi G et al., 2004). Giant cell carcinoma 
components are seen much more commonly in patients 
who have undergone radiation (Radice PA, et al., 1982; 
Masashi G et al., 2004). In this patient, there are three 
component: large cell carcinoma, adenocarcinoma and 
squamous cell carcinoma.
 The classification of  lung cancer has always 
been primarily based on the morphologic assessment of  
routinely stained histological sections, but this approach 
may be difficult or even unfeasible in cytological 
preparations or small biopsies. A more accurate 
characterization of  NSCLC, however, may be hard in 
carcinomas lacking clear-cut signs of  differentiation. But 
the incorporation into the diagnostic algorithm of poorly 
differentiated carcinomas of  an immunohistochemical 
panel including markers of  squamous (high-molecular-
weight cytokeratins, p63), glandular (TTF-1, cytokeratin 
7) cell and neuroendocrine differentiation (synaptophysin, 
CD56, and chromogranin, Bcl-2) seems to be the most 
promising (Kargi A et al., 2007).
The limfonode biopsy specimen of this patient was 
stained by AE1/3, P63, CK7, TTF-1 and chromoganin. 
The evaluation of  lung cancer for gene mutations, gene 
amplification, tumor-related angiogenesis, expression 
levels of  DNA repair genes and genomic or proteomic 
profiles represents an exciting challenge for the 
pathologist in the near future. With the approval and 
use of  newer “molecularly targeted” agents revealing 
differential efficacies in specific subtypes and variants of  
NSCLC, it is becoming more important for pathologists 
to correctly subclassify NSCLC’s as distinct tumor 
entities, or as components of  c-SCLC. 
CONCLUSION
The histopathologic distinction between small 
cell and non small cell lung cancer is the basis for most 
clinical decisions in the management of  pulmonary 
neoplasm. The existence of  neoplasm with mixed small 
cell and non small cell differentiation on a smoker- old, 
untreated patient is particularly indicative of  c-SCLC. 
It is remain unclear wether these tumors represent as 
separate histologic variant of  lung cancer, a subtype 
of  small cell cancer, or even a treatment- induced 
morphologic chance. 
Diagnosing c-SCLC case based on the 
morphologic assessment of  routinely stained 
histological sections may be difficult or even unfeasible 
in cytological preparations or small biopsies. The 
incorporation into the diagnostic algorithm of  poorly 
differentiated carcinomas of  an immunohistochemical 
panel including markers of  squamous (high-molecular-
weight cytokeratins, p63), glandular (TTF-1, cytokeratin 
7) cell and neuroendokrin differentiation (synaptophysin, 
CD56, chromogranin, and Bcl-2) seems to be the most 
promising approach. 
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